Cargando…
Checkpoint Controls and Targets in Cancer Therapy
There is no question that loss of cell cycle checkpoint regulation is an intrinsic characteristic of cancer. However, many tumors retain parallel checkpoint pathways that are activated by antitumor agents and facilitate therapeutic response. Failures in these therapy-linked checkpoint controls are...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2009.
|
| Edición: | 1st ed. 2009. |
| Colección: | Cancer Drug Discovery and Development,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-60761-178-3 | ||
| 003 | DE-He213 | ||
| 005 | 20220118045025.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100715s2009 xxu| s |||| 0|eng d | ||
| 020 | |a 9781607611783 |9 978-1-60761-178-3 | ||
| 024 | 7 | |a 10.1007/978-1-60761-178-3 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Checkpoint Controls and Targets in Cancer Therapy |h [electronic resource] / |c edited by Zahid H. Siddik. |
| 250 | |a 1st ed. 2009. | ||
| 264 | 1 | |a Totowa, NJ : |b Humana Press : |b Imprint: Humana, |c 2009. | |
| 300 | |a XIV, 274 p. 43 illus., 13 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 505 | 0 | |a Circuitry of Checkpoint Response -- Evasion of G1 Checkpoints in Cancer -- Distinct Pathways Involved in S-Phase Checkpoint Control -- Mechanisms of G2 Phase Arrest in DNA Damage-Induced Checkpoint Response -- Centrosomes in Checkpoint Responses -- Interplay of 14-3-3 Family of Proteins with DNA Damage-Regulated Molecules in Checkpoint Control -- Checkpoint Response and the Aetiology of Cancer -- Chromatin Modifications and Orchestration of Checkpoint Response in Cancer -- DNA Damage Response and the Balance Between Cell Survival and Cell Death -- Dysfunction of the RB Retinoblastoma Gene in Cancer -- G1 Phase Cyclins in Cancer Development and Progression -- The BRCA1/2 Pathway Prevents Some Leukemias and Lymphomas in Addition to Breast/Ovarian Cancers: Malignancies that Overcome Checkpoint Controls -- Targeting Checkpoint Response in Cancer Therapy -- Regulation of p53 Activity and Associated Checkpoint Controls -- The Importance of p53 Signaling in the Response of Cells to Checkpoint Inhibitors -- Targeting p21-Dependent Pathways for Cell Death in Cancer Therapy -- p27Kip1 as a Biomarker and Target for Treatment of Cancer -- Targeting Cyclin-Dependent Kinases with Small Molecule Inhibitors -- Chk1 and Chk2 as Checkpoint Targets -- Targeting Cdc25 Phosphatases in Cancer Therapy. | |
| 520 | |a There is no question that loss of cell cycle checkpoint regulation is an intrinsic characteristic of cancer. However, many tumors retain parallel checkpoint pathways that are activated by antitumor agents and facilitate therapeutic response. Failures in these therapy-linked checkpoint controls are closely associated with cancers that are highly resistant to therapeutic interventions. Checkpoint Controls and Targets in Cancer provides present-day mechanistic understandings of how multiple sets of proteins orchestrate cell cycle progression, discusses critical checkpoint controls that are evaded for cancer development, focuses on checkpoint pathways associated with antitumor effects, and identifies specific checkpoint regulators for targeting with small molecules in the clinical management of cancer. These aspects of cell cycle checkpoints are articulated critically by renowned experts from both academia and industry, and new concepts are forwarded that challenge existing dogmas. Collectively, Checkpoint Controls and Targets in Cancer provides a unique collection of insightful contributions, which are timely and offer significant interest and appeal to basic, translational and clinical scientists. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Pharmacology. |
| 700 | 1 | |a Siddik, Zahid H. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781607611844 |
| 776 | 0 | 8 | |i Printed edition: |z 9781607611776 |
| 776 | 0 | 8 | |i Printed edition: |z 9781617796357 |
| 830 | 0 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-60761-178-3 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||